sciencedirect.com/science/a...
in a nutshell:
1 - Deep and Durable PSA Response: The combination therapy produced a significant number of patients achieving undetectable PSA levels (<0.2 ng/ml). Approximately 67% of the patients reached undetectable PSA at some point, with variations based on disease volume—62% in high-volume and 84% in low-volume disease subgroups.
2 - Time to PSA Progression: Darolutamide extended the time to PSA progression substantially compared to placebo, with hazard ratios indicating a significant risk reduction in both high- and low-volume disease groups.
3 - Clinical Outcomes and PSA Suppression: Achieving undetectable PSA levels correlated strongly with longer overall survival (OS) and delayed progression to castration-resistant prostate cancer (CRPC). In particular, undetectable PSA levels at weeks 24 and 36 after treatment initiation were associated with improved outcomes, emphasizing the importance of reaching and maintaining low PSA levels.
4 - Safety Profile: The therapy was well-tolerated, with adverse events aligning with those expected for the treatments used.